Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
A solid budget helps young professionals manage irregular income and set aside funds for future goals.
19,978 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Palantir rides a wave of AI-driven demand as shares hover around $113. A fresh forecast calls for meaningful upside o...
As electric-vehicle charging scales up, ChargePoint's 2026 earnings outlook becomes a key signal for investors. This ...
Micron Technology rides the AI memory wave, but a blowout earnings report invites questions. This guide breaks down t...
Bitcoin ETF inflows topped $1 billion over three days, reviving talk of BTC as a market hedge. Traders weigh the sust...
Cardano shows a near-term buy signal, but traders warn the rebound could be brief as ADA tests key support amid a vol...
A soon-to-retire investor outlines a simple, income-centric ETF strategy built around three funds—JEPQ, DIVO, and SPH...
Snap co-founder Evan Spiegel and Miranda Kerr are funding a California medical debt relief program, potentially wipin...
As Baidu surges, a hedge fund’s multi-million bet raises questions about AI, China’s digital economy, and portfolio c...
As SpaceX IPO chatter grows, investors seek breadth over a single-name bet. A diversified space ETF offers exposure t...
When a royal title doubles as a career asset, it creates a unique financial landscape. This piece examines how prince...
A two-day pension fund rebalance could move about $30 billion of U.S. stocks, posing near-term volatility but often a...